Although the pandemic gave a boost to the drug discovery market, accelerated development in the market will be influenced by effective use of data and analytics.
Renata Maia joins the agency from IPG Health’s award-winning AREA 23.
The COVID-19 pandemic compelled the industry to re-examine the way it conducted clinical trials, engaged with patients, and promoted to HCPs. Companies began to explore decentralized clinical trials, new non-personal promotion strategies, virtual customer engagement strategies, and new ways to engage with the patient — all with an eye toward replacing status quo processes and technologies. The result was the accelerated development of new clinical and commercial technologies and data with the ultimate goal of bringing new therapies to patients faster.
The healthcare marketing and analytics leader expands their Measurement Suite to include unprecedented audience and campaign insights.
Changes are ahead for professionals in life sciences sales and marketing, and medical affairs. From the widening gap between AI-users and those companies still holding out; to the next evolution in AI, and how companies will seek to make it more practical on a global scale; to the impact of AI on leveraging digital opinion leaders to get more clinical evidence in the hands of doctors, Aktana offers its predictions for the coming year.
The use of artificial intelligence and natural language processing is already transforming the process of systematic literature reviews – which means better research, better information for healthcare communicators, and better outcomes for patients.
Vaccines company Valneva on Monday reported positive 12-month antibody persistence data for its single-shot Chikungunya vaccine candidate.
Lumanity’s deep data analytics, value demonstration, and therapeutic area expertise alongside HealthVerity’s patient identity resolution technology and leading ecosystem of interoperable real-world data enables evidence generation across the pharma lifecycle.
The head of the panel of 18 appointees, known as STIKO, said there was no clear case for broad use, citing a lack of data to rule out any rare side effects and no signs of the infection causing severe illness in otherwise healthy children.
GSK is planning a Phase III trial evaluating bepirovirsen as a potential functional cure for chronic hepatitis B infection, despite the most recently released data appearing less robust than the interim analyses. The trial is expected to begin in the first half of 2023.